Fierce Pharma
J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
pharmaphorum
J&J adds first new indication for Caplyta since takeover
The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...
Pharmaceutical Technology on MSN
J&J’s Caplyta wins MDD approval to extend revenue horizon
"J&J’s Caplyta wins MDD approval to extend revenue horizon" was originally created and published by Pharmaceutical Technology ...
BioPharma Dive
J&J brain drug acquired in $14.6B buyout cleared for broader use
Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...
Stocktwits on MSN
Johnson & Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder
The new approval is the first for the drug under JNJ leadership. ・The drug is also approved for the treatment of bipolar I ...